Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1999 1
2000 1
2004 1
2007 1
2010 1
2011 1
2012 2
2013 1
2014 3
2015 1
2016 6
2017 1
2018 3
2019 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
om92 , a glp-1 enhancer mutation, is an allele of ekl-1.
Stein SA, Zucaro OF, Smith HE, O'Connell KF, Spoerke JM, Maine EM, Lissemore JL. Stein SA, et al. Among authors: spoerke jm. MicroPubl Biol. 2022 Nov 30;2022:10.17912/micropub.biology.000698. doi: 10.17912/micropub.biology.000698. eCollection 2022. MicroPubl Biol. 2022. PMID: 36530475 Free PMC article.
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR. Hatzivassiliou G, et al. Among authors: spoerke jm. Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8. Mol Cancer Ther. 2012. PMID: 22402123
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Pan Z, et al. Among authors: spoerke jm. ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221. ChemMedChem. 2007. PMID: 17154430 No abstract available.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K. Bardia A, et al. Among authors: spoerke jm. Breast Cancer Res Treat. 2023 Jan;197(2):319-331. doi: 10.1007/s10549-022-06797-9. Epub 2022 Nov 19. Breast Cancer Res Treat. 2023. PMID: 36401732 Free PMC article.
Molecular biomarker analyses using circulating tumor cells.
Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR. Punnoose EA, et al. Among authors: spoerke jm. PLoS One. 2010 Sep 8;5(9):e12517. doi: 10.1371/journal.pone.0012517. PLoS One. 2010. PMID: 20838621 Free PMC article.
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E. Schöffski P, et al. Among authors: spoerke jm. Breast Cancer Res. 2018 Sep 5;20(1):109. doi: 10.1186/s13058-018-1015-x. Breast Cancer Res. 2018. PMID: 30185228 Free PMC article. Clinical Trial.
27 results